Position in GNLX
as of Mar 31, 2026
· filed May 18, 2026
Position Value
$24,200
-$19,400 QoQ
Shares Held
10,000
0.0% QoQ
Ownership
0.022%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GNLX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026CENTAURUS FINANCIAL, INC. holds $4,932,922 across 11 Biotechnology names. GNLX ranks #11 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
23,174 | $1,497,735 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,721 | $1,215,035 | |
| 3 | AUPH |
Aurinia Pharmaceuticals Inc.
|
61,020 | $904,316 | |
| 4 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
709 | $371,140 | |
| 5 | MRNA |
Moderna, Inc.
|
4,477 | $227,431 | |
| 6 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
2,314 | $201,248 | |
| 7 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
7,249 | $179,485 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
195 | $150,664 |
All Filings in GNLX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $24,200 | 10,000 | Shares | Sole | 2026-05-18 | |
| 2025-12-31 | $43,600 | 10,000 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $42,000 | 10,000 | Shares | Sole | 2025-11-20 | |
| 2025-06-30 | $28,700 | 10,000 | Shares | Sole | 2025-08-29 | |
| 2025-03-31 | $27,000 | 10,000 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $23,600 | 10,000 | Shares | Sole | 2025-03-12 | |
| No filing history on record for this holder in this stock. | ||||||